Smokers switching exclusively to glo significantly reduce exposure to certain toxicants

New research by BAT has found that smokers who switched completely from smoking cigarettes to using BAT’s flagship tobacco heating product (THP), glo, substantially reduced their exposure to certain cigarette smoke toxicants over three months. For many of the toxicants measured, the levels found in participants were similar to those in people that stopped using…

Details

SARS-CoV-2 uses ‘genome origami’ to infect and replicate inside host cells

Scientists at the University of Cambridge, in collaboration with Justus-Liebig University, Germany, have uncovered how the genome of SARS-CoV-2 – the coronavirus that causes COVID-19 – uses genome origami to infect and replicate successfully inside host cells. This could inform the development of effective drugs that target specific parts of the virus genome, in the…

Details

De novo protein decoys block COVID-19 infection in vitro and protect animals in vivo

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2. This report details the creation of de novo protein decoys that were specifically…

Details

Llama nanobodies could be a powerful weapon against COVID-19

PITTSBURGH, Nov. 5, 2020 – Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19. These special llama antibodies, called “nanobodies,” are much…

Details

Nanobodies that neutralize SARS-CoV-2

Two separate studies have identified nanobodies – which could be produced less expensively than monoclonal antibodies – that bind tightly to the SARS-CoV-2 spike protein and efficiently neutralize SARS-CoV-2 in cells. “The combined stability, potency, and diverse epitope engagement of our … nanobodies … provide a unique potential prophylactic and therapeutic strategy to limit the…

Details

Stable protein decoy neutralized SARS-CoV-2 in cells and protected hamsters from viral challenge

Researchers have designed a protein “decoy” that mimics the interface where the SARS-CoV-2 spike protein binds a human cell, one version of which could neutralize virus infection in cells and protect hamsters from viral challenge. The SARS-CoV-2 virus enters human cells when the spike protein binds to the human ACE2 receptor. While neutralizing antibodies to…

Details

Keeping our cool

Fossil fuel burning accounts for the majority of global greenhouse gas emissions, and to the world’s credit, several countries are working to reduce their use and the heat-trapping emissions that ensue. The goal is to keep global temperatures under a 1.5° to 2°C increase above preindustrial levels — the upper limits of the Paris Climate…

Details

Pediatric IBD Foundation, ImproveCareNow, C-Path establish CREATE safety registry

TUCSON, Ariz., November 5, 2020 — The Pediatric IBD Foundation, ImproveCareNow, and the Critical Path Institute (C-Path) are proud to announce a collaboration establishing the Children’s Registry for the Advancement of Therapeutics (CREATE™). CREATE™ is a drug-agnostic safety registry designed to support the completion of global post-marketing safety requirements, as well as collect safety information…

Details